115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
黄芪甲苷 IV 通过抑制 GNG2/MRAS-ERK 信号通路改善糖尿病性心肌病
Authors Dong Y, Ma Y, Liu SJ, Zhang HY, Li G, Yan S, Fu Q
Received 2 June 2025
Accepted for publication 10 December 2025
Published 8 January 2026 Volume 2026:19 544287
DOI https://doi.org/10.2147/IJGM.S544287
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Redoy Ranjan
Ying Dong,1,* Yidi Ma,2,* Shi-Jan Liu,3 Hong-Yan Zhang,4 Gen Li,5 Shi Yan,6 Qiang Fu2
1The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People’s Republic of China; 2School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People’s Republic of China; 3Department of Kidney, the Second Affliated of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China; 4Department of Kidney, Beidahuang Industry Group General Hospital, Harbin, Heilongjiang, People’s Republic of China; 5Department of Radiation Therapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China; 6Medical Oncology, Cancer Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shi Yan, Email jj.snake@163.com Qiang Fu, Email fuqiang@hljucm.edu.cn
Objective: This study aims to investigate the mechanism of AGS-IV in treating diabetic cardiomyopathy (DCM) by establishing animal and cellular models of the disease.
Methods: A DCM rat model was established by feeding a high-fat diet combined with streptozotocin (STZ) injection, and a DCM cell model was created through glucose induction. In model rats, the cardiac weight-to-body weight ratio, the left ventricular weight-to-heart weight ratio, and ventricular wall thickness were measured. ELISA was used to detect Collagen1 and MMP-2 levels in myocardial tissue, serum, and cultured cells. The mRNA levels of GNG2, MRAS, and ERK in myocardial tissue and cultured cells were measured using RT-PCR.
Results: In vivo, experiments demonstrated that AGS-IV effectively reduced the cardiac weight-to-body weight ratio, left ventricular weight-to-heart weight ratio, and ventricular wall thickness in DCM rat models. It also decreased Collagen I levels in myocardial tissue and MMP-2 levels in serum, accompanied by downregulated mRNA expression of GNG2, MRAS, and ERK in myocardial tissue. In vitro, AGS-IV significantly reduced Collagen I and MMP-2 levels in DCM cell models and downregulated GNG2, MRAS, and ERK mRNA expression.
Conclusion: AGS-IV exerts therapeutic effects on DCM by regulating the GNG2/MRAS-ERK signaling pathway.
Keywords: AGS-IV, diabetic cardiomyopathy, in vivo, in vitro
1The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People’s Republic of China; 2School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People’s Republic of China; 3Department of Kidney, the Second Affliated of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China; 4Department of Kidney, Beidahuang Industry Group General Hospital, Harbin, Heilongjiang, People’s Republic of China; 5Department of Radiation Therapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China; 6Medical Oncology, Cancer Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shi Yan, Email jj.snake@163.com Qiang Fu, Email fuqiang@hljucm.edu.cn
Objective: This study aims to investigate the mechanism of AGS-IV in treating diabetic cardiomyopathy (DCM) by establishing animal and cellular models of the disease.
Methods: A DCM rat model was established by feeding a high-fat diet combined with streptozotocin (STZ) injection, and a DCM cell model was created through glucose induction. In model rats, the cardiac weight-to-body weight ratio, the left ventricular weight-to-heart weight ratio, and ventricular wall thickness were measured. ELISA was used to detect Collagen1 and MMP-2 levels in myocardial tissue, serum, and cultured cells. The mRNA levels of GNG2, MRAS, and ERK in myocardial tissue and cultured cells were measured using RT-PCR.
Results: In vivo, experiments demonstrated that AGS-IV effectively reduced the cardiac weight-to-body weight ratio, left ventricular weight-to-heart weight ratio, and ventricular wall thickness in DCM rat models. It also decreased Collagen I levels in myocardial tissue and MMP-2 levels in serum, accompanied by downregulated mRNA expression of GNG2, MRAS, and ERK in myocardial tissue. In vitro, AGS-IV significantly reduced Collagen I and MMP-2 levels in DCM cell models and downregulated GNG2, MRAS, and ERK mRNA expression.
Conclusion: AGS-IV exerts therapeutic effects on DCM by regulating the GNG2/MRAS-ERK signaling pathway.
Keywords: AGS-IV, diabetic cardiomyopathy, in vivo, in vitro